These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 11877273)

  • 1. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy.
    Rossig C; Bollard CM; Nuchtern JG; Rooney CM; Brenner MK
    Blood; 2002 Mar; 99(6):2009-16. PubMed ID: 11877273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.
    Rossig C; Bär A; Pscherer S; Altvater B; Pule M; Rooney CM; Brenner MK; Jürgens H; Vormoor J
    J Immunother; 2006; 29(1):21-31. PubMed ID: 16365597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
    Savoldo B; Rooney CM; Di Stasi A; Abken H; Hombach A; Foster AE; Zhang L; Heslop HE; Brenner MK; Dotti G
    Blood; 2007 Oct; 110(7):2620-30. PubMed ID: 17507664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells.
    Altvater B; Pscherer S; Landmeier S; Niggemeier V; Juergens H; Vormoor J; Rossig C
    Clin Exp Immunol; 2006 Jun; 144(3):447-57. PubMed ID: 16734614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy.
    Pizzitola I; Agostoni V; Cribioli E; Pule M; Rousseau R; Finney H; Lawson A; Biondi A; Biagi E; Marin V
    J Immunother; 2011; 34(6):469-79. PubMed ID: 21654519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
    Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
    J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting CD19 with genetically modified EBV-specific human T lymphocytes.
    Roessig C; Scherer SP; Baer A; Vormoor J; Rooney CM; Brenner MK; Juergens H
    Ann Hematol; 2002; 81 Suppl 2():S42-3. PubMed ID: 12611072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
    Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
    Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor.
    Nakazawa Y; Huye LE; Salsman VS; Leen AM; Ahmed N; Rollins L; Dotti G; Gottschalk SM; Wilson MH; Rooney CM
    Mol Ther; 2011 Dec; 19(12):2133-43. PubMed ID: 21772253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
    Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
    Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
    Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP
    Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease.
    Dolcetti R; Frisan T; Sjöberg J; De Campos-Lima PO; Pisa P; De Re V; Gloghini A; Rizzo S; Masucci MG; Boiocchi M
    Cancer Res; 1995 Aug; 55(16):3675-81. PubMed ID: 7627978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease.
    Sing AP; Ambinder RF; Hong DJ; Jensen M; Batten W; Petersdorf E; Greenberg PD
    Blood; 1997 Mar; 89(6):1978-86. PubMed ID: 9058719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes.
    Baxevanis CN; Papamichail M
    Cancer Immunol Immunother; 2004 Oct; 53(10):893-903. PubMed ID: 15168086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
    Gargett T; Brown MP
    Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes.
    Ramadan G
    Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
    Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
    J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells.
    Moosmann A; Khan N; Cobbold M; Zentz C; Delecluse HJ; Hollweck G; Hislop AD; Blake NW; Croom-Carter D; Wollenberg B; Moss PA; Zeidler R; Rickinson AB; Hammerschmidt W
    Blood; 2002 Sep; 100(5):1755-64. PubMed ID: 12176897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65.
    Sun Q; Pollok KE; Burton RL; Dai LJ; Britt W; Emanuel DJ; Lucas KG
    Blood; 1999 Nov; 94(9):3242-50. PubMed ID: 10556213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.